Amélie Lusque
150 works · 4,663 citations · h-index 27
Top works
- Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
- Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
- Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer
- Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial
- Abstract PD8-02: Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: A phase II study with biomarkers analysis (DAISY)
- Genomics to select treatment for patients with metastatic breast cancer
- PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab
- Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial
- Lymph node excisions provide more precise lymphoma diagnoses than core biopsies: a French Lymphopath network survey
- Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial
- Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort
- Overexpression of Claspin and Timeless protects cancer cells from replication stress in a checkpoint-independent manner
- Breast desmoid tumor management in France: toward a new strategy
- Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients
- Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large Multicentric Cohort Study: A Propensity Score-Matched Analysis
- LBA1 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial
- Subventricular zones: new key targets for glioblastoma treatment
- Body Mass Index as a Major Risk Factor for Severe Breast Cancer-Related Lymphedema
- 260P Antitumor activity of trastuzumab deruxtecan (T-DXd) in patients with metastatic breast cancer (mBC) and brain metastases (BMs) from DAISY trial
- Radiation therapy to the primary tumor for de novo metastatic breast cancer and overall survival in a retrospective multicenter cohort analysis